Net Sales are expected to decrease by 4.2 percent Y-o-Y (down 5.9 percent Q-o-Q) to Rs 2,841.6 crore, according to Prabhudas Lilladher.

Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher

Net Sales are expected to increase by 5.1 percent Y-o-Y (down 5.3 percent Q-o-Q) to Rs 3,006.1 crore, according to Prabhudas Lilladher.

Glenmark Pharmaceuticals Q3 PAT seen up 17.8% YoY to Rs 292.4 cr: Prabhudas Lilladher

Net Sales are expected to increase by 10.3 percent Y-o-Y (down 2.4 percent Q-o-Q) to Rs 3,073.1 crore, according to Prabhudas Lilladher.

Glenmark Pharmaceuticals Q2 PAT seen up 18.4% YoY to Rs 269.5 cr: Prabhudas Lilladher

Net Sales are expected to decrease by 4.2 percent Y-o-Y (down 5.4 percent Q-o-Q) to Rs 2,786.7 crore, according to Prabhudas Lilladher.

Glenmark Pharma Q1 PAT seen up 23.3% YoY to Rs 313.1 cr: KRChoksey

Net Sales are expected to increase by 23.1 percent Y-o-Y (up 1 percent Q-o-Q) to Rs 2,887 crore, according to KRChoksey.

Glenmark Pharmaceuticals Q3 PAT seen up 27.4% YoY to Rs. 190.8 cr: Prabhudas Lilladher

Net Sales are expected to increase by 5.5 percent Y-o-Y (down 4.3 percent Q-o-Q) to Rs. 2,638.6 crore, according to Prabhudas Lilladher.

Glenmark Q2 PAT may dip 46% YoY to Rs. 132.8 cr: Emkay

Net Sales are expected to increase by 2.4 percent Y-o-Y (up 13.8 percent Q-o-Q) to Rs. 2,642.7 crore, according to Emkay.

Glenmark Pharma Q1 PAT may dip 44.8% YoY to Rs. 151.7 cr: Prabhudas Lilladher

Net Sales are expected to increase by 5.6 percent Y-o-Y (down 11 percent Q-o-Q) to Rs. 2,247.9 crore, according to Prabhudas Lilladher.

Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell

Elara Capital which has reduce rating on stock said FY19 operating performance remained weak, given lack of meaningful US sales.

Glenmark Pharmaceuticals Q4 PAT seen up 30% YoY to Rs. 196.4 cr: Prabhudas Lilladher

Net Sales are expected to increase by 10.8 percent Y-o-Y (down 0.8 percent Q-o-Q) to Rs. 2,490.2 crore, according to Prabhudas Lilladher.

Glenmark Q3 PAT seen up 96.7% YoY to Rs. 206.5 cr: Sharekhan

Net Sales are expected to increase by 13.2 percent Y-o-Y (down 3.4 percent Q-o-Q) to Rs. 2,494 crore, according to Sharekhan.

Glenmark Q3 PAT seen up 121.5% YoY to Rs. 232 cr: ICICI Direct

Net Sales are expected to increase by 14.4 percent Y-o-Y (down 2.3 percent Q-o-Q) to Rs. 2,521 crore, according to ICICI Direct.

Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila

For Lupin, Credit Suisse sees margin improving but weak Tamiflu season could be an overhang.

Glenmark Pharma Q2 PAT seen up 2.8% YoY to Rs. 210 cr: HDFC Securities

Net Sales are expected to increase by 10.3 percent Y-o-Y (up 15.2 percent Q-o-Q) to Rs. 2,450 crore, according to HDFC Securities.

Glenmark Q2 PAT may dip 22% YoY to Rs. 167 cr: Sharekhan

Net Sales are expected to increase by 5.1 percent Y-o-Y (up 9.5 percent Q-o-Q) to Rs. 2,372.4 crore, according to Sharekhan.

Glenmark Q2 PAT seen up 1.7% YoY to Rs. 217.8 cr: ICICI Direct

Net Sales are expected to increase by 12.6 percent Y-o-Y (up 17.3 percent Q-o-Q) to Rs. 2,540 crore, according to ICICI Direct.

Pharma Q1 preview: Poised for strong performance on rebound of domestic and stable US generics biz

"For the first time after six consecutive quarters, the pharma companies under our coverage will report double digit YoY growth of 13 percent in revenues,” said HDFC Securities

Glenmark Pharma Q4 PAT seen up 711.4% YoY to Rs. 170 cr: HDFC Securities

Net Sales are expected to decrease by 15 percent Y-o-Y (down 5.1 percent Q-o-Q) to Rs. 2,060 crore, according to HDFC Securities.

Glenmark Pharma Q4 PAT may dip 27.7% YoY to Rs. 173.7 cr: Edelweiss

Net Sales are expected to decrease by 8.5 percent Y-o-Y (up 2 percent Q-o-Q) to Rs. 2,247.6 crore, according to Edelweiss.

Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key

Analysts predict the last quarter of FY18 to be mixed bag with revenues expected to remain almost flat to a growth of lower single digit on year-on-year basis. The net profit is predicted to decline by around 9-10 percent.

Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue

While addressing conference call, Glenn Saldanha, Chairman and MD said the US business continued to be very challenging and that pricing pressure would remain challenging for 5 quarters.

Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key

As Indian drug makers brace up to report their third quarter earnings in the days ahead, analysts predict Q3 FY18 to be mixed bag with revenues expected to remain flat on year-on-year basis, though on sequential basis things may look much better.

Not looking at M&A as growth opportunity, would like to grow organically: Glenmark

Glenmark Pharma posted stable quarter with a slowdown seen in their Indian business. In an interview to CNBC-TV18, Glenn Saldanha, CMD of Glenmark spoke about the results and his outlook for the company.

Have buy rating on Glenmark Pharma: HDFC Securities

In an interview to CNBC-TV18, Amey Chalke of HDFC Securities spoke about Q1 FY18 earnings from pharma sector.

Glenmark Pharma Q1 profit seen up 13% at Rs 257 cr, revenue growth may be 17%

Revenue growth is expected to be led by US business. Within US, street is factoring in a better performance from cholesterol drug Zetia generic that was launched in December with exclusivity; ended in June.